FDA Cites Lovelace Biomedical Research Institute in 2026-10-06 Warning Letter — Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies
Letter issued · posted to fda.gov .
Subject as published: Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies
TL;DR
Here's the summary: On October 6, 2026, the FDA Center for Drug Evaluation and Research issued a Warning Letter to Lovelace Biomedical Research Institute (LBRI), Albuquerque, NM, following an inspection conducted April 7-18, 2025, citing violations of Good Laboratory Practice regulations (21 CFR 58) for nonclinical drug studies. The FDA found that LBRI's quality assurance unit failed to ensure final study reports accurately reflected raw data, specifically omitting abnormal clinical observations documented in 20 of 34 animals and multiple dosing incidents (catheter pulls, tissue infiltration, irregular breathing, dosing refusals) across two study protocols.
Argus analysis
# FDA Warning Letter Analysis: Lovelace Biomedical Research Institute
## Overview
The FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter to Lovelace Biomedical Research Institute (LBRI) in Albuquerque, New Mexico on October 6, 2026, following an inspection conducted April 7–18, 2025. The inspection examined nonclinical laboratory studies for investigational drugs conducted at the facility. FDA investigators identified significant deficiencies in how the quality assurance unit (QAU) reviewed and reported study data, raising concerns about data integrity across multiple protocols involving animal testing.
## Regulatory Citations
The violations center on 21 CFR 58.35(b)(6), which requires the QAU to review final study reports to ensure reported results accurately reflect raw data from nonclinical laboratory studies. This regulation is foundational to the Good Laboratory Practice (GLP) framework governing nonclinical testing. LBRI's QAU failed to document abnormal clinical observations—such as sneezing, bloody nose, and stool abnormalities recorded in 20 of 34 animals—and omitted critical dosing incidents including catheter dislodgement, tissue infiltration, and breathing irregularities. These gaps occurred across at least two study protocols. GLP compliance ensures the quality and scientific validity of data submitted to support drug development.
## Next Steps and Industry Watch Points
LBRI had 15 business days from letter receipt to submit corrective actions. The initial May 2025 response was deemed inadequate because it lacked specifics on Standard Operating Procedure updates, staff training plans, and internal audit procedures to verify ongoing compliance. Peer compliance officers should monitor whether LBRI submits a comprehensive follow-up response addressing these gaps. The warning letter signals FDA's heightened scrutiny of testing facilities' QAU functions. Similar facilities should expect increased inspection focus on raw data traceability and completeness of final reports, particularly for animal observations and protocol deviations.
Severity context
Low severity. Procedural or narrow scope; most peer companies resolve in the 15-business-day response window without structural change.
Regulatory background
FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Lovelace Biomedical Research Institute MARCS-CMS 725136 — October 06, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Product: Drugs Recipient: Recipient Name Robert W. Rubin Recipient Title CEO Lovelace Biomedical Research Institute 2425 Ridgecrest Drive SE Albuquerque , NM 87108 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER FDA Ref. No.: 27-HFD-45-10-01 Dear Mr. Rubin: This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Lovelace Biomedical Research Institute (LBRI) between April 7 and 18, 2025. The investigator representing FDA reviewed the role of LBRI as the testing facility for the following nonclinical laboratory studies: Protocol (b)(4) : “ (b)(4) ,” of the investigational drug (b)(4) , performed for (b)(4) Protocol (b)(4) : “ (b)(4) ,” of the investigational drug (b)(4) , performed for (b)(4) This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2025, written response to the Form FDA 483. From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following: Failure of the quality assurance unit (QAU) to review the final study report to [en]sure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)]. The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol (b)(4) , the following observations found in the raw data were not documented in the final study report: 1. For 20 out of 34 animals, the final study report did not include all the abnormal cageside clinical observations that were documented between October 1 and January 3, 2024, including but not limited to sneezing; runny or bloody nose; liquid, loose, mucoid, or semisolid stool; sunken eyes; swollen perineum; bloating; hunched posture; low appetite; and heavy breathing. …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Warning Letter warning letter?
- FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Lovelace Biomedical Research Institute had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Lovelace Biomedical Research Institute as of 2026-10-13. Argus ingests new FDA enforcement records daily.
- What FDA violations was Lovelace Biomedical Research Institute cited for?
- The FDA Warning Letter to Lovelace Biomedical Research Institute (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. Classification: Warning Letter.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Lovelace Biomedical Research Institute in 2026-10-06 Warning Letter — Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-lovelace-biomedical-research-institute-2026-10-06-warning-letter
"FDA Cites Lovelace Biomedical Research Institute in 2026-10-06 Warning Letter — Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-lovelace-biomedical-research-institute-2026-10-06-warning-letter.
Argus HQ Research. "FDA Cites Lovelace Biomedical Research Institute in 2026-10-06 Warning Letter — Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies." Digital Empire Holdings LLC. Accessed October 14, 2026. https://argushq.ai/fda/warning-letter/fda-wl-lovelace-biomedical-research-institute-2026-10-06-warning-letter.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_lovelace_biomedical_research_institute_2026_10_06_warning_letter_2026,
title = {FDA Cites Lovelace Biomedical Research Institute in 2026-10-06 Warning Letter — Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-lovelace-biomedical-research-institute-2026-10-06-warning-letter},
note = {Accessed: October 14, 2026}
}